Leprosy, also known as Hansen's disease (HD), is a long-term infection by the bacteria Mycobacterium leprae or Mycobacterium lepromatosis.[4][8] Initially, a person who is infected does not have symptoms and typically remains this way for 5 to 20 years.[4] Infection can lead to damage of the nerves, respiratory tract, skin, and eyes.[4] This nerve damage may result in a lack of ability to feel pain, which can lead to the loss of parts of a person's extremities from repeated injuries or infection due to unnoticed wounds.[3] An infected person may also experience weakness and poor eyesight.[3]

Other namesHansen's disease (HD)[1]
Rash on the chest and abdomen due to leprosy
  • /ˈlɛprəsi/[2]
SpecialtyInfectious disease
SymptomsDecreased ability to feel pain[3]
CausesMycobacterium leprae or Mycobacterium lepromatosis[4][5]
Risk factorsClose contact with a case of leprosy, living in poverty[3][6]
TreatmentMultidrug therapy[4]
MedicationRifampicin, dapsone, clofazimine[3]
Frequency514,000 (2015)[7]

Leprosy is spread between people, although extensive contact is necessary.[3][9] About 95% of people who contact M. leprae do not develop the disease.[10] Spread is thought to occur through a cough or contact with fluid from the nose of a person infected by leprosy.[9][10] Leprosy does not spread during pregnancy to the unborn children or through sexual contact.[9] Leprosy occurs more commonly among people living in poverty.[3] Genetic factors and immune function play a role in how easily a person catches the disease.[10][11] The two main types of disease – paucibacillary and multibacillary – differ in the number of bacteria present.[3] A person with paucibacillary disease has five or fewer poorly pigmented numb skin patches while a person with multibacillary disease has more than five.[3] The diagnosis is confirmed by finding acid-fast bacilli in a biopsy of the skin or by detecting the bacteria's DNA using polymerase chain reaction.[3]

Leprosy is curable with multidrug therapy.[4] Treatment of paucibacillary leprosy is with the medications dapsone, rifampicin, and clofazimine for six months.[10] Treatment for multibacillary leprosy uses the same medications for 12 months.[10] A number of other antibiotics may also be used.[3] These treatments are provided free of charge by the World Health Organization.[4] People with leprosy can live with their families and go to school and work.[12] At the end of 2016, there were 173,000 leprosy cases globally, down from 5.2 million in the 1980s.[4][13][14] The number of new cases in 2016 was 216,000.[4] Most new cases occur in 14 countries, with India accounting for more than half.[3][4] In the past 20 years, 16 million people worldwide have been cured of leprosy.[4] About 200 cases per year are reported in the United States.[15]

Leprosy has affected humanity for thousands of years.[3] The disease takes its name from the Greek word λέπρᾱ (léprā), from λεπῐ́ς (lepís; "scale"), while the term "Hansen's disease" is named after the Norwegian physician Gerhard Armauer Hansen.[3] Leprosy has historically been associated with social stigma, which continues to be a barrier to self-reporting and early treatment.[4] Separating people affected by leprosy by placing them in leper colonies still occurs in some areas of India,[16] China,[17] and Africa.[18] However, most colonies have closed, since leprosy is not very contagious.[18] Some consider the word "leper" offensive, preferring the phrase "person affected with leprosy".[19] Leprosy is classified as a neglected tropical disease.[20] World Leprosy Day was started in 1954 to draw awareness to those affected by leprosy.[21]

Signs and symptoms

Leprosy can affect people in different ways.[10] The first noticeable sign of leprosy is often the development of pale or pink coloured patches of skin that may be insensitive to temperature or pain.[22] Patches of discolored skin are sometimes accompanied or preceded by nerve problems including numbness or tenderness in the hands or feet.[22][23] Secondary infections (additional bacterial or viral infections) can result in tissue loss, causing fingers and toes to become shortened and deformed, as cartilage is absorbed into the body.[24][25]

Approximately 30% of people affected with leprosy experience nerve damage.[26] The nerve damage sustained is reversible when treated early, but becomes permanent when appropriate treatment is started after a delay of several months. Damage to nerves may cause loss of muscle function, leading to paralysis. It may also lead to sensation abnormalities or numbness, which may lead to additional infections, ulcerations, and joint deformities.[26]


M. leprae and M. lepromatosis

M. leprae, one of the causative agents of leprosy: As an acid-fast bacterium, M. leprae appears red when a Ziehl-Neelsen stain is used.

M. leprae and M. lepromatosis are the mycobacterium that cause leprosy.[26] M. lepromatosis is a relatively newly identified mycobacterium isolated from a fatal case of diffuse lepromatous leprosy in 2008.[5][27] M. lepromatosis is indistinguishable clinically from M. leprae.[28]

M. leprae is an intracellular, acid-fast bacterium that is aerobic and rod-shaped.[29] M. leprae is surrounded by the waxy cell membrane coating characteristic of the genus Mycobacterium.[29]

Genetically, M. leprae and M. lepromatosis lack the genes that are necessary for independent growth.[30] M. leprae and M. lepromatosis are obligate intracellular pathogens, and can not be grown (cultured) in the laboratory.[30] The inability to culture M. leprae and M. lepromatosis has resulted in a difficulty definitively identifying the bacterial organism under a strict interpretation of Koch's postulates.[5][30]

While the causative organisms have to date been impossible to culture in vitro, it has been possible to grow them in animals such as mice and armadillos.[31][32]

Naturally occurring infection has been reported in nonhuman primates (including the African chimpanzee, the sooty mangabey, and the cynomolgus macaque), armadillos,[33] and red squirrels.[34] Multilocus sequence typing of the armadillo M. leprae strains suggests that they were of human origin for at most a few hundred years.[35] Thus, it is suspected that armadillos first acquired the organism incidentally from early American explorers.[36] This incidental transmission was sustained in the armadillo population, and it may be transmitted back to humans, making leprosy a zoonotic disease (spread between humans and animals).[36]

Red squirrels (Sciurus vulgaris), a threatened species in Great Britain, were found to carry leprosy in November 2016.[37] It has been suggested that the trade in red squirrel fur, highly prized in the medieval period and intensively traded, may have been responsible for the leprosy epidemic in medieval Europe.[38] A pre-Norman-era skull excavated in Hoxne, Suffolk, in 2017 was found to carry DNA from a strain of Mycobacterium leprae, which closely matched the strain carried by modern red squirrels on Brownsea Island, UK.[38][39]

Risk factors

The greatest risk factor for developing leprosy is contact with another person infected by leprosy.[4] People who are exposed (in contact) with a person who has leprosy are 5-8 times more likely to develop leprosy than members of the general population.[6] Leprosy also occurs more commonly among those living in poverty.[3] Not all people who are infected with M. leprae develop symptoms.[40][41]

Conditions that reduce immune function, such as malnutrition, other illnesses, or genetic mutations, may increase the risk of developing leprosy.[6] Infection with HIV does not appear to increase the risk of developing leprosy.[42] Certain genetic factors in the person exposed have been associated with developing lepromatous or tuberculoid leprosy.[43]


Transmission of leprosy occurs during close contact with those who are infected.[4] Transmission of leprosy is not well understood, but the upper respiratory tract is thought to be the most likely entry route.[10][44] Older research suggested the skin as the main route of transmission, but recent research has increasingly favored the respiratory route.[45]

Leprosy is not sexually transmitted and is not spread through pregnancy to the unborn child.[4][9] The majority (95%) of people who are exposed to M. Leprae do not develop leprosy; casual contact such as shaking hands and sitting next to someone with leprosy does not lead to transmission.[4][46] People are considered non-infectious 72 hours after starting appropriate multidrug therapy.[47]

Two exit routes of M. leprae from the human body often described are the skin and the nasal mucosa, although their relative importance is not clear. Lepromatous cases show large numbers of organisms deep in the dermis, but whether they reach the skin surface in sufficient numbers is doubtful.[48]

Leprosy may also be transmitted to humans by armadillos, although the mechanism is not fully understood.[9][49][50]


Name Locus OMIM Gene
LPRS1 10p13 609888
LPRS2 6q25 607572 PARK2, PACRG
LPRS3 4q32 246300 TLR2
LPRS4 6p21.3 610988 LTA
LPRS5 4p14 613223 TLR1
LPRS6 13q14.11 613407

Not all people who are infected or exposed to M. leprae develop leprosy, and genetic factors are suspected to play a role in susceptibility to an infection.[51] Cases of leprosy often cluster in families and several genetic variants have been identified.[51] In many people who are exposed, the immune system is able to eliminate the leprosy bacteria during the early infection stage before severe symptoms develop.[52] A genetic defect in cell-mediated immunity may cause a person to be susceptible to develop leprosy symptoms after exposure to the bacteria.[53] The region of DNA responsible for this variability is also involved in Parkinson's disease, giving rise to current speculation that the two disorders may be linked at the biochemical level.[53]


There is limited evidence to determine the mechanism underlying how M. leprae produces the symptoms of leprosy.[14]

M. leprae has been shown to bind to schwann cells, which may lead to nerve injury including demyelination and a loss of nerve function (specifically a loss of axonal conductance).[54] Numerous molecular mechanisms have been associated with this nerve damage including the presence of a laminin-binding protein and the glycoconjugate (PGL-1) on the surface of M. leprae that can bind to laminin on peripheral nerves.[54]

As part of the human immune response, white blood cell-derived macrophages may engulf M. leprae by phagocytosis.[54]


Testing for loss of sensation with monofilament

In countries where people are frequently infected, a person is considered to have leprosy if they have one of the following two signs:

  • Skin lesion consistent with leprosy and with definite sensory loss.[55]
  • Positive skin smears.[55]

Skin lesions can be single or many, and usually hypopigmented, although occasionally reddish or copper-colored.[55] The lesions may be flat (macules), raised (papules), or solid elevated areas (nodular).[55] Experiencing sensory loss at the skin lesion is a feature that can help determine if the lesion is caused by Leprosy or if the lesion is caused by another disorder such as tinea versicolor.[55][56] Thickened nerves are associated with leprosy and can be accompanied by loss of sensation or muscle weakness, however, without the characteristic skin lesion and sensory loss, muscle weakness is not considered a reliable sign of leprosy.[55]

In some cases, acid-fast leprosy bacilli in skin smears are considered diagnostic; however, the diagnosis is clinical.[55]

In countries or areas where leprosy is uncommon, such as the United States, diagnosis of leprosy is often delayed because healthcare providers are unaware of leprosy and its symptoms.[57] Early diagnosis and treatment prevent nerve involvement, the hallmark of leprosy, and the disability it causes.[4][57]

Common symptoms present in the different types of leprosy include a runny nose; dry scalp; eye problems; skin lesions; muscle weakness; reddish skin; smooth, shiny, diffuse thickening of facial skin, ear, and hand; loss of sensation in fingers and toes; thickening of peripheral nerves; a flat nose due to destruction of nasal cartilage; phonation and resonation of sound during speech.[58][59] In addition, atrophy of the testes and impotence may occur.[60] A person's immune response differs depending on the form of leprosy.[61]

There is no recommended test to diagnose latent leprosy in people without symptoms.[10] Few people with latent leprosy test positive for anti PGL-1.[40]


Several different approaches for classifying leprosy exist. There are similarities between the classification approaches.

  • The World Health Organization system distinguishes "paucibacillary" and "multibacillary" based upon the proliferation of bacteria.[62] ("pauci-" refers to a low quantity.)
  • The Ridley-Jopling scale provides five gradations.[63][64][65]
  • The ICD-10, though developed by the WHO, uses Ridley-Jopling and not the WHO system. It also adds an indeterminate ("I") entry.[48]
  • In MeSH, three groupings are used.
WHO Ridley-Jopling ICD-10 MeSH Description Lepromin test
Paucibacillary tuberculoid ("TT"),
tuberculoid ("BT")
A30.1, A30.2 Tuberculoid It is characterized by one or more hypopigmented skin macules and patches where skin sensations are lost because of damaged peripheral nerves that have been attacked by the human host's immune cells. Positive
Multibacillary midborderline
borderline ("BB")
A30.3 Borderline Borderline leprosy is of intermediate severity and is the most common form. Skin lesions resemble tuberculoid leprosy, but are more numerous and irregular; large patches may affect a whole limb, and peripheral nerve involvement with weakness and loss of sensation is common. This type is unstable and may become more like lepromatous leprosy or may undergo a reversal reaction, becoming more like the tuberculoid form.
Multibacillary borderline lepromatous ("BL"),
and lepromatous ("LL")
A30.4, A30.5 Lepromatous It is associated with symmetric skin lesions, nodules, plaques, thickened dermis, and frequent involvement of the nasal mucosa resulting in nasal congestion and nose bleeds, but, typically, detectable nerve damage is late. Loss of eyebrows and lashes can be seen in advanced disease.[66] Negative

Leprosy may also occur with only neural involvement, without skin lesions.[4][67][68][69][70][71]


Early detection of the disease is important, since physical and neurological damage may be irreversible even if cured.[4] Medications can decrease the risk of those living with people with leprosy from acquiring the disease and likely those with whom people with leprosy come into contact outside the home.[14] The WHO recommends that preventative medicine is given to people who are in close contact with someone who has leprosy.[10] The suggested preventative treatment is a single dose of rifampicin (SDR) in adults and children over 2 years old who do not already have leprosy or tuberculosis.[10] Preventative treatment is associated with a 57% reduction in infections within 2 years and a 30% reduction in infections within 6 years.[10]

The Bacillus Calmette–Guérin (BCG) vaccine offers a variable amount of protection against leprosy in addition to its target of tuberculosis.[72] It appears to be 26% to 41% effective (based on controlled trials) and about 60% effective based on observational studies with two doses possibly working better than one.[73][74] The WHO concluded in 2018 that the BCG vaccine at birth reduces leprosy risk and is recommended in countries with high incidence of TB and leprosy.[75] Development of a more effective vaccine is ongoing.[14][76][77][78]


MDT antileprosy drugs: standard regimens from 2010

Anti-leprosy medication

A number of leprostatic agents are available for treatment. A 3-drug regimen of rifampicin, dapsone and clofazimine is recommended for all people with leprosy, for 6 months for paucibacillary leprosy and 12 months for multibacillary leprosy.[10]

Multidrug therapy (MDT) remains highly effective, and people are no longer infectious after the first monthly dose.[4] It is safe and easy to use under field conditions due to its presentation in calendar blister packs.[4] Post-treatment relapse rates remain low.[4] Resistance has been reported in several countries, although the number of cases is small.[79] People with rifampicin-resistant leprosy may be treated with second line drugs such as fluoroquinolones, minocycline, or clarithromycin, but the treatment duration is 24 months due to their lower bactericidal activity.[80] Evidence on the potential benefits and harms of alternative regimens for drug-resistant leprosy is not yet available.[10]

Skin changes and Plantar ulcers

For people with nerve damage, protective footwear may help prevent ulcers and secondary infection.[26] Canvas shoes may be better than PVC-boots.[26] There may be no difference between double rocker shoes and below-knee plaster.[26]. The mechanism of plantar ulceration in leprosy and its treatment was first described by Dr Ernest W Price.[81]

Topical ketanserin seems to have a better effect on ulcer healing than clioquinol cream or zinc paste, but the evidence for this is weak.[26] Phenytoin applied to the skin improves skin changes to a greater degree when compared to saline dressings.[26]


World distribution of leprosy, 2016
Disability-adjusted life year for leprosy per 100,000 inhabitants in 2004[82]
  no data

In 2016, there were 216,108 new cases of leprosy registered, corresponding to a global detection rate of 0.29 per 10,000 people.[83] In 2015, 94% of the new leprosy cases were confined to 14 countries.[84] India reported the greatest number of new cases (60% of reported cases), followed by Brazil (13%) and Indonesia (8%).[84] Although the number of cases worldwide continues to fall, there are parts of the world where leprosy is more common, including, Brazil, South Asia (India, Nepal, Bhutan), some parts of Africa (Tanzania, Madagascar, Mozambique), and the western Pacific.[84] About 150 to 250 cases are diagnosed in the United States each year.[85]

In the 1960s, there were tens of millions of leprosy cases recorded when the bacteria started to develop resistance to dapsone, the most common treatment option at the time.[4][14] International (e.g., the WHO's "Global Strategy for Reducing Disease Burden Due to Leprosy") and national (e.g., the International Federation of Anti-Leprosy Associations) initiatives and have reduced the total number and the number of new cases of the disease.[14][86]

Disease burden

The number of new leprosy cases is difficult to measure and monitor due to leprosy's long incubation period, delays in diagnosis after onset of the disease, and lack of medical care in affected areas.[87] The registered prevalence of the disease is used to determine disease burden.[88] Registered prevalence is a useful proxy indicator of the disease burden, as it reflects the number of active leprosy cases diagnosed with the disease and receiving treatment with MDT at a given point in time.[88] The prevalence rate is defined as the number of cases registered for MDT treatment among the population in which the cases have occurred, again at a given point in time.[88]


G. H. A. Hansen, discoverer of M. leprae

Using comparative genomics, in 2005, geneticists traced the origins and worldwide distribution of leprosy from East Africa or the Near East along human migration routes. They found four strains of M. leprae with specific regional locations. Strain 1 occurs predominantly in Asia, the Pacific region, and East Africa; strain 4, in West Africa and the Caribbean; strain 3 in Europe, North Africa, and the Americas; and strain 2 only in Ethiopia, Malawi, Nepal/north India, and New Caledonia.

On the basis of this, they offer a map of the dissemination of leprosy in the world. This confirms the spread of the disease along the migration, colonisation, and slave trade routes taken from East Africa to India, West Africa to the New World, and from Africa into Europe and vice versa.[89]

The oldest skeletal evidence for the disease date from 2000 BC, as found in human remains from the archaeological sites of Balathal in India and Harappa in Pakistan.[90][91]

Although retrospectively identifying descriptions of leprosy-like symptoms is difficult, what appears to be leprosy was discussed by Hippocrates in 460 BC. In 1846, Francis Adams produced The Seven Books of Paulus Aegineta which included a commentary on all medical and surgical knowledge and descriptions and remedies to do with leprosy from the Romans, Greeks, and Arabs.[92]

Interpretations of the presence of leprosy have been made on the basis of descriptions in ancient Indian (Atharva Veda and Kausika Sutra), Greek, and Middle Eastern documentary sources that describe skin afflictions.[93]

Leprosy probably did not exist in Greece or the Middle East before Common Era.[94][95][96] It did not exist in the Americas before colonization by modern Europeans.[97] It did not exist in Polynesia until the middle of the 19th century.[98]

Skeletal remains from the second millennium BC, discovered in 2009, represent the oldest documented evidence for leprosy. Located at Balathal, in Rajasthan, northwest India, the discoverers suggest that if the disease did migrate from Africa to India, during the third millennium BC "at a time when there was substantial interaction among the Indus Civilization, Mesopotamia, and Egypt, there needs to be additional skeletal and molecular evidence of leprosy in India and Africa so as to confirm the African origin of the disease."[99] A proven human case was verified by DNA taken from the shrouded remains of a man discovered in a tomb next to the Old City of Jerusalem dated by radiocarbon methods to 1–50 AD.[100]

Distribution of leprosy around the world in 1891

However, a study published in 2018 found the oldest strains of leprosy in remains from Europe, the oldest strain being from Great Chesterford and dating back to 415 to 545 AD. These findings suggest a different path for the spread of leprosy, meaning it may have originated in Western Eurasia. This study also indicates that there were more strains in Europe at the time than previously determined.[101]

The causative agent of leprosy, M. leprae, was discovered by G. H. Armauer Hansen in Norway in 1873, making it the first bacterium to be identified as causing disease in humans.[102]

The first effective treatment (promin) became available in the 1940s.[103] In the 1950s, dapsone was introduced. The search for further effective antileprosy drugs led to the use of clofazimine and rifampicin in the 1960s and 1970s.[104] Later, Indian scientist Shantaram Yawalkar and his colleagues formulated a combined therapy using rifampicin and dapsone, intended to mitigate bacterial resistance.[105] Multi-drug therapy (MDT) combining all three drugs was first recommended by the WHO in 1981. These three antileprosy drugs are still used in the standard MDT regimens.

Leprosy was once believed to be highly contagious and was treated with mercury, as was syphilis, which was first described in 1530. Many early cases thought to be leprosy could actually have been syphilis.[106]

Resistance has developed to initial treatment. Until the introduction of MDT in the early 1980s, leprosy could not be diagnosed and treated successfully within the community.[107]

Japan still has sanatoriums (although Japan's sanatoriums no longer have active leprosy cases, nor are survivors held in them by law).[108]

The importance of the nasal mucosa in the transmission of M leprae was recognized as early as 1898 by Schäffer, in particular, that of the ulcerated mucosa.[109]

Society and culture

Two lepers denied entrance to town, 14th century

The word "leprosy" comes from the Greek word "λέπος (lépos) – skin" and "λεπερός (leperós) – scaly man.


British India enacted the Leprosy Act of 1898 which institutionalized those affected and segregated them by sex to prevent reproduction. The Act was difficult to enforce but was repealed in 1983 only after MDT had become widely available. In 1983, the National Leprosy Elimination Programme, previously the National Leprosy Control Programme, changed its methods from surveillance to the treatment of people with leprosy. India still accounts for over half of the global disease burden.[110]

Treatment cost

Between 1995 and 1999, the WHO, with the aid of the Nippon Foundation, supplied all endemic countries with free MDT in blister packs, channeled through ministries of health.[111] This free provision was extended in 2000 and again in 2005, 2010 and 2015 with donations by the MDT manufacturer Novartis through the WHO. In the latest agreement signed between the company and the WHO in October 2015, the provision of free MDT by the WHO to all endemic countries will run until the end of 2020.[111] At the national level, nongovernment organizations affiliated with the national program will continue to be provided with an appropriate free supply of MDT by the WHO.[112]

Historical texts

Written accounts of leprosy date back thousands of years. Various skin diseases translated as leprosy appear in the ancient Indian text, the Atharava Veda, by 600 BC.[113] Another Indian text, the Manusmriti (1500 BC),  prohibited contact with those infected with the disease and made marriage to a person infected with leprosy punishable.[114]

Biblically speaking, the Hebraic root tsara or tsaraath (צָרַע,—tsaw-rah'—to be struck with leprosy, to be leprous) and the Greek (λεπρός—lepros), are of broader classification than the more narrow use of the term related to Hansen's Disease.[115] Any progressive skin disease (a whitening or splotchy bleaching of skin, raised manifestations of scales, scabs, infections, rashes, etc....) as well as generalized molds and surface discoloration of any clothing, leather, and/or discoloration on walls surfaces throughout homes all came under the "law of leprosy" (Leviticus 14:54–57).[116] Ancient sources also such as the Talmud (Sifra 63) make clear that tzaraath refers to various types of lesions or stains associated with ritual impurity and occurring on cloth, leather, or houses, as well as skin. The New Testament describes instances of Jesus healing people with leprosy in Luke 17:11, although the relationship between this disease, tzaraath, and Hansen's disease is not established.

The biblical perception that people with leprosy were unclean may be connected to a passage from Leviticus 13: 44–46, which indicated that leprosy was of moral consequence. Early Christians believed that those affected by leprosy were being punished by God for sinful behavior. Moral associations have persisted throughout history. Pope Gregory the Great (540–604) and Isidor of Seville (560–636) considered people with the disease to be heretics.[117]

Middle Ages

Medieval leper bell

It is believed that a rise in leprosy in Europe occurred in the Middle Ages based on the increased number of hospitals created to treat people with leprosy in the 12th and 13th centuries.[118][119][120] France alone had nearly 2,000 leprosariums during this period.[121]

The social perception of leprosy in medieval communities was generally one of fear, and people infected with the disease were thought to be unclean, untrustworthy, and morally corrupt.[117] Segregation from mainstream society was common, and people with leprosy were often required to wear clothing that identified them as such or carry a bell announcing their presence.[121] The third Lateran Council of 1179 and a 1346 edict by King Edward expelled lepers from city limits. Because of the moral stigma of the disease, methods of treatment were both physical and spiritual, and leprosariums were established under the purview of the church.[117][122]

19th century

A 24-year-old man with leprosy (1886)


Norway was the location of a progressive stance on leprosy tracking and treatment and played an influential role in European understanding of the disease. In 1832, Dr. JJ Hjort conducted the first leprosy survey, thus establishing a basis for epidemiological surveys. Subsequent surveys resulted in the establishment of a national leprosy registry to study the causes of leprosy and for tracking of the rate of infection.

Early leprosy research throughout Europe was conducted by Norwegian scientists Daniel Cornelius Danielssen and Carl Wilhelm Boeck. Their work resulted in the establishment of the National Leprosy Research and Treatment Center. Danielssen and Boeck believed the cause of leprosy transmission was hereditary. This stance was influential in advocating for the isolation of those infected by sex to prevent reproduction.[123][124][125]

Colonialism and imperialism

Father Damien on his deathbed in 1889

Though leprosy in Europe was again on the decline by the 1860s, Western countries embraced isolation treatment out of fear of the spread of disease from developing countries, minimal understanding of bacteriology, lack of diagnostic ability or knowledge of how contagious the disease was, and missionary activity.[110] Growing imperialism and pressures of the industrial revolution resulted in a Western presence in countries where leprosy was endemic, namely the British presence in India. Isolation treatment methods were observed by Surgeon-Mayor Henry Vandyke Carter of the British Colony in India while visiting Norway, and these methods were applied in India with the financial and logistical assistance of religious missionaries. Colonial and religious influence and associated stigma continued to be a major factor in the treatment and public perception of leprosy in endemic developing countries until the mid-twentieth century.[110]


Despite effective treatment and education efforts, leprosy stigma continues to be problematic in developing countries where the disease is common. Leprosy is most common amongst impoverished or marginalized populations where social stigma is likely to be compounded by other social inequities. Fears of ostracism, loss of employment, or expulsion from family and society may contribute to a delayed diagnosis and treatment.

Folk beliefs, lack of education, and religious connotations of the disease continue to influence social perceptions of those afflicted in many parts of the world. In Brazil, for example, folklore holds that leprosy is transmitted by dogs, it is a disease associated with sexual promiscuity, and is sometimes thought to be punishment for sins or moral transgressions.[126] Socioeconomic factors also have a direct impact. Lower-class domestic workers who are often employed by those in a higher socioeconomic class may find their employment in jeopardy as physical manifestations of the disease become apparent. Skin discoloration and darker pigmentation resulting from the disease also have social repercussions.

In extreme cases in northern India, leprosy is equated with an "untouchable" status that "often persists long after (individuals with leprosy) have been cured of the disease, creating lifelong prospects of divorce, eviction, loss of employment, and ostracism from family and social networks."[127]

Programs and treatment

The WHO states that diagnosis and treatment with MDT are easy and effective, and a 45% decline in disease burden has occurred since MDT has become more widely available. The organization emphasizes the importance of fully integrating leprosy treatment into public health services, effective diagnosis and treatment, and access to information.[128]

In some instances in India, community-based rehabilitation is embraced by local governments and NGOs alike. Often, the identity cultivated by a community environment is preferable to reintegration, and models of self-management and collective agency independent of NGOs and government support have been desirable and successful.[129]

Notable cases

  • Saint Damien De Veuster, a Roman Catholic priest from Belgium, himself eventually contracting leprosy, ministered to lepers who had been placed under a government-sanctioned medical quarantine on the island of Molokaʻi in the Kingdom of Hawaiʻi.[130]
  • Baldwin IV of Jerusalem was a Christian king of Latin Jerusalem afflicted with leprosy.[131]
  • King Henry IV of England (reigned 1399 to 1413) possibly had leprosy.[132]
  • Vietnamese poet Hàn Mặc Tử[133]
  • Ōtani Yoshitsugu, a Japanese daimyō[134]
  • Forough Farrokhzad made a 22-minute documentary about a leprosy colony in Iran in 1962 called The House Is Black. The film humanizes the people affected and opens by saying that "there is no shortage of ugliness in the world, but by closing our eyes on ugliness, we will intensify it."

Other animals

Wild nine-banded armadillos (Dasypus novemcinctus) in south central United States often carry Mycobacterium leprae.[135] This is believed to be because armadillos have such a low body temperature. Leprosy lesions appear mainly in cooler body regions such as the skin and mucous membranes of the upper respiratory tract. Because of armadillos' armor, skin lesions are hard to see.[136] Abrasions around the eyes, nose and feet are the most common signs. Infected armadillos make up a large reservoir of M. leprae and may be a source of infection for some humans in the United States or other locations in the armadillos' home range. In armadillo leprosy, lesions did not persist at the site of entry in animals, M. leprae multiplied in macrophages at the site of inoculation and lymph nodes.[137]

See also

  • Kate Marsden


  1. Worobec, SM (2008). "Treatment of leprosy/Hansen's disease in the early 21st century". Dermatologic Therapy. 22 (6): 518–37. doi:10.1111/j.1529-8019.2009.01274.x. PMID 19889136.
  2. "Definition of leprosy". The Free Dictionary. Retrieved 2015-01-25.
  3. Suzuki K, Akama T, Kawashima A, Yoshihara A, Yotsu RR, Ishii N (February 2012). "Current status of leprosy: epidemiology, basic science and clinical perspectives". The Journal of Dermatology. 39 (2): 121–9. doi:10.1111/j.1346-8138.2011.01370.x. PMID 21973237.
  4. "Leprosy Fact sheet N°101". World Health Organization. January 2014. Archived from the original on 2013-12-12.
  5. "New Leprosy Bacterium: Scientists Use Genetic Fingerprint To Nail 'Killing Organism'". ScienceDaily. 2008-11-28. Archived from the original on 2010-03-13. Retrieved 2010-01-31.
  6. Schreuder, P.A.M.; Noto, S.; Richardus J.H. (January 2016). "Epidemiologic trends of leprosy for the 21st century". Clinics in Dermatology. 34 (1): 24–31. doi:10.1016/j.clindermatol.2015.11.001. PMID 26773620.
  7. GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
  8. Sotiriou, MC; Stryjewska, BM; Hill, C (7 September 2016). "Two Cases of Leprosy in Siblings Caused by Mycobacterium lepromatosis and Review of the Literature". The American Journal of Tropical Medicine and Hygiene. 95 (3): 522–7. doi:10.4269/ajtmh.16-0076. PMC 5014252. PMID 27402522.
  9. "Hansen's Disease (Leprosy) Transmission". cdc.gov. April 29, 2013. Archived from the original on 13 March 2015. Retrieved 28 February 2015.
  10. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. https://apps.who.int/iris/bitstream/handle/10665/274127/9789290226383-eng.pdf?ua=1: World Health Organization. 2018. pp. xiii. ISBN 978-92-9022-638-3.
  11. Montoya, D; Modlin, RL (2010). "Learning from leprosy: insight into the human innate immune response". Advances in Immunology. 105: 1–24. doi:10.1016/S0065-2776(10)05001-7. ISBN 9780123813022. PMID 20510728.
  12. CDC (2018-01-26). "World Leprosy Day". Centers for Disease Control and Prevention. Retrieved 2019-07-04.
  13. "Global leprosy situation, 2012". Wkly. Epidemiol. Rec. 87 (34): 317–28. August 2012. PMID 22919737.
  14. Rodrigues LC; Lockwood DNj (June 2011). "Leprosy now: epidemiology, progress, challenges, and research gaps". The Lancet Infectious Diseases. 11 (6): 464–70. doi:10.1016/S1473-3099(11)70006-8. PMID 21616456.
  15. "Hansen's Disease Data & Statistics". Health Resources and Services Administration. Archived from the original on 4 January 2015. Retrieved 12 January 2015.
  16. Walsh F (2007-03-31). "The hidden suffering of India's lepers". BBC News. Archived from the original on 2007-05-29.
  17. Lyn TE (2006-09-13). "Ignorance breeds leper colonies in China". Independat News & Media. Archived from the original on 2010-04-08. Retrieved 2010-01-31.
  18. Byrne, Joseph P. (2008). Encyclopedia of pestilence, pandemics, and plagues. Westport, Conn.[u.a.]: Greenwood Press. p. 351. ISBN 978-0-313-34102-1.
  19. editors, Enrico Nunzi, Cesare Massone (2012). Leprosy a practical guide. Milan: Springer. p. 326. ISBN 978-88-470-2376-5. Archived from the original on 2017-09-08.
  20. "Neglected Tropical Diseases". cdc.gov. June 6, 2011. Archived from the original on 4 December 2014. Retrieved 28 November 2014.
  21. McMenamin, Dorothy (2011). Leprosy and stigma in the South Pacific : a region-by-region history with first person accounts. Jefferson, N.C.: McFarland. p. 17. ISBN 978-0-7864-6323-7. Archived from the original on 2016-05-19.
  22. WHO Expert Committee on Leprosy - Eight report (PDF). World Health Organization. 2012. pp. 11–12. ISBN 9789241209687. Retrieved 9 May 2018.
  23. Talhari C, Talhari S, Penna GO (2015). "Clinical aspects of leprosy". Clinics in Dermatology. 33 (1): 26–37. doi:10.1016/j.clindermatol.2014.07.002. PMID 25432808.
  24. Kulkarni GS (2008). Textbook of Orthopedics and Trauma (2nd ed.). Jaypee Brothers Publishers. p. 779. ISBN 978-81-8448-242-3.
  25. "Q and A about leprosy". American Leprosy Missions. Archived from the original on 2012-10-04. Retrieved 2011-01-22. Do fingers and toes fall off when someone gets leprosy? No. The bacillus attacks nerve endings and destroys the body's ability to feel pain and injury. Without feeling pain, people injure themselves on fire, thorns, rocks, even hot coffee cups. Injuries become infected and result in tissue loss. Fingers and toes become shortened and deformed as the cartilage is absorbed into the body.
  26. Reinar, Liv Merete; Forsetlund, Louise; Lehman, Linda Faye; Brurberg, Kjetil G (2019-07-31). Cochrane Skin Group (ed.). "Interventions for ulceration and other skin changes caused by nerve damage in leprosy". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD012235.pub2.
  27. Ryan, Kenneth J.; Ray, C. George, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 451–3. ISBN 978-0-8385-8529-0. OCLC 61405904.
  28. "Genomics Insights into the Biology and Evolution of Leprosy Bacilli". International Textbook of Leprosy. 2016-02-11. Retrieved 2019-02-11.
  29. McMurray DN (1996). "Mycobacteria and Nocardia". In Baron S; et al. (eds.). Baron's Medical Microbiology (4th ed.). Univ of Texas Medical Branch. ISBN 978-0-9631172-1-2. OCLC 33838234. Archived from the original on 2009-02-12.
  30. Bhattacharya S, Vijayalakshmi N, Parija SC (1 October 2002). "Uncultivable bacteria: Implications and recent trends towards identification". Indian Journal of Medical Microbiology. 20 (4): 174–7. PMID 17657065. Archived from the original on 27 September 2007.
  31. "WHO | Microbiology: culture in vitro". WHO. Retrieved 2019-07-22.
  32. admin (2016-02-11). "The Armadillo Model for Leprosy". International Textbook of Leprosy. Retrieved 2019-07-22.
  33. Loughry WJ, Truman RW, McDonough CM, Tilak MK, Garnier S, et al. (2009) "Is leprosy spreading among nine-banded armadillos in the southeastern United States?" J Wildl Dis 45: 144–152.
  34. Meredith, Anna; Del Pozo, Jorge; Smith, Sionagh; Milne, Elspeth; Stevenson, Karen; McLuckie, Joyce (September 2014). "Leprosy in red squirrels in Scotland". Veterinary Record. 175 (11): 285–286. doi:10.1136/vr.g5680. PMID 25234460.
  35. Monot M, Honoré N, Garnier T, Araoz R, Coppee JY, et al. (2005). "On the origin of leprosy". Science 308: 1040–1042.
  36. Han, Xiang Y.; Silva, Francisco J.; Baker, Stephen (13 February 2014). "On the Age of Leprosy". PLoS Neglected Tropical Diseases. 8 (2): e2544. doi:10.1371/journal.pntd.0002544. PMC 3923669. PMID 24551248.
  37. "Red squirrels in the British Isles are infected with leprosy bacilli", Dr. Andrej Benjak, Prof Anna Meredith and others. Science, 11 November 2016. Archived 11 November 2016 at the Wayback Machine. Retrieved 11 November 2016.
  38. "Could squirrel fur trade have contributed to England's medieval leprosy outbreak?". ScienceDaily. Retrieved 21 November 2018.
  39. Inskip, S; Taylor, GM; Anderson, S; Stewart, G (November 2017). "Leprosy in pre-Norman Suffolk, UK: biomolecular and geochemical analysis of the woman from Hoxne" (PDF). Journal of Medical Microbiology. 66 (11): 1640–1649. doi:10.1099/jmm.0.000606. PMID 28984227.
  40. Penna, Maria Lucia F.; Penna, Gerson O.; Iglesias, Paula C.; Natal, Sonia; Rodrigues, Laura C. (2016-05-18). Small, Pamela L. C. (ed.). "Anti-PGL-1 Positivity as a Risk Marker for the Development of Leprosy among Contacts of Leprosy Cases: Systematic Review and Meta-analysis". PLOS Neglected Tropical Diseases. 10 (5): e0004703. doi:10.1371/journal.pntd.0004703. ISSN 1935-2735. PMC 4871561. PMID 27192199.
  41. Alcaïs A, Mira M, Casanova JL, Schurr E, Abel L (2005). "Genetic dissection of immunity in leprosy". Curr. Opin. Immunol. 17 (1): 44–8. doi:10.1016/j.coi.2004.11.006. PMID 15653309.
  42. Lockwood DN, Lambert SM (January 2011). "Human immunodeficiency virus and leprosy: an update". Dermatologic Clinics. 29 (1): 125–8. doi:10.1016/j.det.2010.08.016. PMID 21095536.
  43. admin (2016-02-11). "Epidemiology of Leprosy". International Textbook of Leprosy. Retrieved 2019-07-30.
  44. Chavarro-Portillo, Bibiana; Soto, Carlos Yesid; Guerrero, Martha Inírida (September 2019). "Mycobacterium leprae's evolution and environmental adaptation". Acta Tropica. 197: 105041. doi:10.1016/j.actatropica.2019.105041. ISSN 1873-6254. PMID 31152726.
  45. Eichelmann, K.; González González, S. E.; Salas-Alanis, J. C.; Ocampo-Candiani, J. (2013-09-01). "Leprosy. An Update: Definition, Pathogenesis, Classification, Diagnosis, and Treatment". Actas Dermo-Sifiliográficas (English Edition). 104 (7): 554–563. doi:10.1016/j.adengl.2012.03.028. ISSN 1578-2190. PMID 23870850.
  46. "Hansen's Disease (Leprosy) Transmission". cdc.gov. April 29, 2013. Archived from the original on 13 March 2015. Retrieved 28 February 2015.
  47. Lockwood, Diana N J; Kumar, Bhushan (2004-06-19). "Treatment of leprosy". BMJ : British Medical Journal. 328 (7454): 1447–1448. doi:10.1136/bmj.328.7454.1447. ISSN 0959-8138. PMC 428501. PMID 15205269.
  48. "What Is Leprosy?" THE MEDICAL NEWS | from News-Medical.Net – Latest Medical News and Research from Around the World. Web. 20 Nov. 2010. "What is Leprosy?". 2009-11-18. Archived from the original on 2013-06-06. Retrieved 2013-05-14..
  49. Truman RW, Singh P, Sharma R, Busso P, Rougemont J, Paniz-Mondolfi A, Kapopoulou A, Brisse S, Scollard DM, Gillis TP, Cole ST (April 2011). "Probable Zoonotic Leprosy in the Southern United States". The New England Journal of Medicine. Massachusetts Medical Society. 364 (17): 1626–1633. doi:10.1056/NEJMoa1010536. PMC 3138484. PMID 21524213.
  50. "Hansen's Disease (Leprosy) Transmission". cdc.gov. April 29, 2013. Archived from the original on 13 March 2015. Retrieved 28 February 2015.
  51. Cambri, Geison; Mira, Marcelo Távora (2018-07-20). "Genetic Susceptibility to Leprosy—From Classic Immune-Related Candidate Genes to Hypothesis-Free, Whole Genome Approaches". Frontiers in Immunology. 9: 1674. doi:10.3389/fimmu.2018.01674. ISSN 1664-3224. PMC 6062607. PMID 30079069.
  52. Cook, Gordon C. (2009). Manson's tropical diseases (22nd ed.). [Edinburgh]: Saunders. p. 1056. ISBN 978-1-4160-4470-3. Archived from the original on 2017-09-04.
  53. Buschman E, Skamene E (Jun 2004). "Linkage of leprosy susceptibility to Parkinson's disease genes" (PDF). International Journal of Leprosy and Other Mycobacterial Diseases. 72 (2): 169–70. doi:10.1489/1544-581X(2004)072<0169:LOLSTP>2.0.CO;2. ISSN 0148-916X. PMID 15301585. Archived (PDF) from the original on January 5, 2012. Retrieved January 31, 2011.
  54. Bhat, Ramesh Marne; Prakash, Chaitra (2012). "Leprosy: An Overview of Pathophysiology". Interdisciplinary Perspectives on Infectious Diseases. 2012: 181089. doi:10.1155/2012/181089. ISSN 1687-708X. PMC 3440852. PMID 22988457.
  55. "Diagnosis of Leprosy." WHO. from "WHO | Diagnosis of leprosy". Archived from the original on 2014-06-05. Retrieved 2014-07-14. accessed on 14 July 2014.
  56. Moschella, Samuel L; Garcia-Albea, Victoria (September 2016). "International Textbook of Leprosy" (PDF). Differential Diagnosis of Leprosy. p. 3, Section 2.3. Retrieved July 4, 2019.
  57. U.S. Department of Health and Human Services, Health Resources and Services Administration. (n.d.). National Hansen's disease (leprosy) program Retrieved from "Archived copy". Archived from the original on 2011-02-10. Retrieved 2013-05-12.CS1 maint: archived copy as title (link)
  58. "Signs and Symptoms | Hansen's Disease (Leprosy) | CDC". www.cdc.gov. 2018-10-22. Retrieved 2019-07-22.
  59. "Leprosy Specific Orofacial Aspects". ResearchGate. Retrieved 2019-07-22.
  60. admin (2016-02-11). "Pathogenesis and Pathology of Leprosy". International Textbook of Leprosy. Retrieved 2019-07-22.
  61. de Sousa, Jorge Rodrigues; Sotto, Mirian Nacagami; Simões Quaresma, Juarez Antonio (2017). "Leprosy As a Complex Infection: Breakdown of the Th1 and Th2 Immune Paradigm in the Immunopathogenesis of the Disease". Frontiers in Immunology. 8: 1635. doi:10.3389/fimmu.2017.01635. ISSN 1664-3224. PMC 5712391. PMID 29234318.
  62. Smith DS (2008-08-19). "Leprosy: Overview". eMedicine Infectious Diseases. Archived from the original on 2010-02-18. Retrieved 2010-02-01.
  63. Singh N, Manucha V, Bhattacharya SN, Arora VK, Bhatia A (June 2004). "Pitfalls in the cytological classification of borderline leprosy in the Ridley-Jopling scale". Diagn. Cytopathol. 30 (6): 386–8. doi:10.1002/dc.20012. PMID 15176024.
  64. Ridley DS, Jopling WH; Jopling (1966). "Classification of leprosy according to immunity. A five-group system". Int. J. Lepr. Other Mycobact. Dis. 34 (3): 255–73. PMID 5950347.
  65. James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. pp. 344–346. ISBN 978-0-7216-2921-6.
  66. Kumar, Bhushan; Uprety, Shraddha; Dogra, Sunil (2016-02-11). "Clinical Diagnosis of Leprosy". International Textbook of Leprosy. Retrieved 2019-02-12.
  67. Jardim MR, Antunes SL, Santos AR, et al. (July 2003). "Criteria for diagnosis of pure neural leprosy". J. Neurol. 250 (7): 806–9. doi:10.1007/s00415-003-1081-5. PMID 12883921.
  68. Mendiratta V, Khan A, Jain A (2006). "Primary neuritic leprosy: a reappraisal at a tertiary care hospital". Indian J Lepr. 78 (3): 261–7. PMID 17120509.
  69. Ishida Y, Pecorini L, Guglielmelli E (July 2000). "Three cases of pure neuritic (PN) leprosy at detection in which skin lesions became visible during their course". Nihon Hansenbyo Gakkai Zasshi. 69 (2): 101–6. doi:10.5025/hansen.69.101. PMID 10979277.
  70. Mishra B, Mukherjee A, Girdhar A, Husain S, Malaviya GN, Girdhar BK (1995). "Neuritic leprosy: further progression and significance". Acta Leprol. 9 (4): 187–94. PMID 8711979.
  71. Talwar S, Jha PK, Tiwari VD (September 1992). "Neuritic leprosy: epidemiology and therapeutic responsiveness". Lepr Rev. 63 (3): 263–8. doi:10.5935/0305-7518.19920031. PMID 1406021.
  72. Duthie MS, Gillis TP, Reed SG (November 2011). "Advances and hurdles on the way toward a leprosy vaccine". Hum Vaccin. 7 (11): 1172–83. doi:10.4161/hv.7.11.16848. PMC 3323495. PMID 22048122.
  73. Setia MS, Steinmaus C, Ho CS, Rutherford GW (March 2006). "The role of BCG in prevention of leprosy: a meta-analysis". Lancet Infect Dis. 6 (3): 162–70. doi:10.1016/S1473-3099(06)70412-1. PMID 16500597.
  74. Merle CS, Cunha SS, Rodrigues LC (2010). "BCG vaccination and leprosy protection: Review of current evidence and status of BCG in leprosy control". Expert Review of Vaccines. 9 (2): 209–222. doi:10.1586/ERV.09.161. PMID 20109030.
  75. World Health Organization (June 2018). "BCG vaccine: WHO position paper, February 2018 – Recommendations". Vaccine. 36 (24): 3408–3410. doi:10.1016/j.vaccine.2018.03.009. ISSN 0264-410X. PMID 29609965.
  76. "Leprosy Vaccine". American Leprosy Missions. Archived from the original on November 15, 2015. Retrieved October 20, 2015.
  77. "Trial set for world's first leprosy vaccine". The Guardian. June 6, 2014. Archived from the original on October 11, 2015. Retrieved October 20, 2015.
  78. "China's Mars plans, leprosy vaccine and self-driving taxis". Nature. 537 (7618): 12–13. 2016-08-31. Bibcode:2016Natur.537...12.. doi:10.1038/537012a. PMID 27582199.
  79. "WHO | MDT and drug resistance". WHO. Retrieved 2019-07-22.
  80. Reibel, F.; Cambau, E.; Aubry, A. (2015-09-01). "Update on the epidemiology, diagnosis, and treatment of leprosy". Médecine et Maladies Infectieuses. 45 (9): 383–393. doi:10.1016/j.medmal.2015.09.002. ISSN 0399-077X. PMID 26428602.
  81. Vernon : 096777201988840. doi:10.1177/0967772019888406. PMID 31735101., Gervase. "Dr E W Price, the discoverer of podoconiosis". Journal of Medical Biography. Sage Journals. Retrieved 18 December 2019.
  82. "Mortality and Burden of Disease Estimates for WHO Member States in 2002" (xls). World Health Organization. 2002. Archived from the original on 2013-01-16.
  83. "WHO | Global Leprosy Strategy 2016−2020: Accelerating towards a leprosy-free world". WHO. Retrieved 2019-01-14.
  84. "WHO | Global leprosy update, 2015: time for action, accountability and inclusion". WHO. Retrieved 2019-01-14.
  85. Maggie Veatch (21 Feb 2019). "Leprosy still lurks in United States, study says". CNN.
  86. "About ILEP". ILEP. Archived from the original on 2014-08-12. Retrieved 2014-08-25.
  87. admin (2016-02-11). "Epidemiology of Leprosy". International Textbook of Leprosy. Retrieved 2019-07-23.
  88. World Health Organization. (1985). "Epidemiology of leprosy in relation to control. Report of a WHO Study Group". World Health Organ Tech Rep Ser. Geneva: World Health Organization. 716: 1–60. ISBN 978-92-4-120716-4. OCLC 12095109. PMID 3925646.
  89. Monot, Marc; Honoré, Nadine; Garnier, Thierry; Araoz, Romul; Coppée, Jean-Yves; Lacroix, Céline; Sow, Samba; Spencer, John S.; Truman, Richard W.; Williams, Diana L.; Gelber, Robert; Virmond, Marcos; Flageul, Béatrice; Cho, Sang-Nae; Ji, Baohong; Paniz-Mondolfi, Alberto; Convit, Jacinto; Young, Saroj; Fine, Paul E.; Rasolofo, Voahangy; Brennan, Patrick J.; Cole, Stewart T. (13 May 2005). "On the Origin of Leprosy". Science. 308 (5724): 1040–1042. doi:10.1126/science/1109759. PMID 15894530.
  90. Robbins, G; Mushrif, V.; Misra, V.N.; Mohanty, R.K.; Shinde, V.S.; Gray, K.M.; Schug, M.D. (May 2009). "Ancient skeletal evidence for Leprosy in India (2000 B.C.)". PLoS ONE. 4 (5): e5669. Bibcode:2009PLoSO...4.5669R. doi:10.1371/journal.pone.0005669. PMC 2682583. PMID 19479078.
  91. Robbins Schug, G; Blevins, K. Elaine; Cox, Brett; Gray, Kelsey; Mushrif-Tripathy, Veena (December 2013). "Infection, Disease, and Biosocial Process at the End of the Indus Civilization". PLoS ONE. 8 (12): e84814. Bibcode:2013PLoSO...884814R. doi:10.1371/journal.pone.0084814. PMC 3866234. PMID 24358372.
  92. Francis Adams, The Seven Books of Paulus Aegineta: Translated from the Greek with Commentary Embracing a Complete View of the Knowledge Possessed by the Greeks, Romans and Arabians on all Subjects Connected with Medicine and Surgery, 3 vols. (London: Sydenham Society, 1678
  93. Roman: Celsus, Pliny, Serenus Samonicus, Scribonius Largus, Caelius Aurelianus, Themison, Octavius Horatianus, Marcellus the Emperic; Greek: Aretaeus, Plutarch, Galen, Oribasius, Aetius, Actuarius, Nonnus, Psellus, Leo, Myrepsus; Arabic: Scrapion, Avenzoar, Albucasis, the Haly Abbas translated by Stephanus Antiochensis, Alsharavius, Rhases, and Guido de Cauliaco
  94. William S. Haubrich (2003). Medical Meanings: A Glossary of Word Origins. ACP Press. p. 133. ISBN 978-1-930513-49-5.
  95. Michael Wilkins; Craig A. Evans; Darrell Bock; Andreas J. Köstenberger (1 October 2013). The Gospels and Acts. B&H Publishing Group. p. 194. ISBN 978-1-4336-8101-1.
  96. Encyclopedia of Jewish Medical Ethics: A Compilation of Jewish Medical Law on All Topics of Medical Interest ... Feldheim Publishers. 2003. p. 951. ISBN 978-1-58330-592-8.
  97. Robert I. Rotberg (2001). Population History and the Family: A Journal of Interdisciplinary History Reader. MIT Press. p. 132. ISBN 978-0-262-68130-8.
  98. Montgomerie, John Z. (1988). "Leprosy in New Zealand". Journal of the Polynesian Society. 97 (2): 115–152. Retrieved 3 September 2019.
  99. Robbins, Gwen; Tripathy, V. Mushrif; Misra, V. N.; Mohanty, R. K.; Shinde, V. S.; Gray, Kelsey M.; Schug, Malcolm D. (May 27, 2009). "Ancient Skeletal Evidence for Leprosy in India (2000 B.C.)". PLoS ONE. 4 (5): e5669. Bibcode:2009PLoSO...4.5669R. doi:10.1371/journal.pone.0005669. PMC 2682583. PMID 19479078.
  100. "DNA of Jesus-Era Shrouded Man in Jerusalem Reveals Earliest Case of Leprosy". ScienceDaily. 2009-12-16. Archived from the original on 2009-12-20. Retrieved 2010-01-31.
  101. Schuenemann, Verena J.; Avanzi, Charlotte; Krause-Kyora, Ben; Seitz, Alexander; Herbig, Alexander; Inskip, Sarah; Bonazzi, Marion; Reiter, Ella; Urban, Christian; Dangvard Pedersen, Dorthe; Taylor, G. Michael; Singh, Pushpendra; Stewart, Graham R.; Velemínský, Petr; Likovsky, Jakub; Marcsik, Antónia; Molnár, Erika; Pálfi, György; Mariotti, Valentina; Riga, Alessandro; Belcastro, M. Giovanna; Boldsen, Jesper L.; Nebel, Almut; Mays, Simon; Donoghue, Helen D.; Zakrzewski, Sonia; Benjak, Andrej; Nieselt, Kay; Cole, Stewart T.; Krause, Johannes (2018). "Ancient genomes reveal a high diversity of Mycobacterium leprae in medieval Europe". PLOS Pathogens. 14 (5): e1006997. doi:10.1371/journal.ppat.1006997. PMC 5944922. PMID 29746563.
  102. Irgens LM (2002). "The discovery of the leprosy bacillus". Tidsskr nor Laegeforen. 122 (7): 708–9. PMID 11998735.
  103. Andrew Baum; et al. (1997). Cambridge handbook of psychology, health and medicine. Cambridge, Angleterre: Cambridge University Press. p. 521. ISBN 978-0-521-43686-1. Archived from the original on 2016-06-11.
  104. Rees RJ, Pearson JM, Waters MF (1970). "Experimental and Clinical Studies on Rifampicin in Treatment of Leprosy". Br Med J. 688 (1): 89–92. doi:10.1136/bmj.1.5688.89. PMC 1699176. PMID 4903972.
  105. Yawalkar SJ, McDougall AC, Languillon J, Ghosh S, Hajra SK, Opromolla DV, Tonello CJ (1982). "Once-monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy". Lancet. 319 (8283): 1199–1202. doi:10.1016/S0140-6736(82)92334-0. PMID 6122970.
  106. Syphilis through history Archived 2013-05-13 at the Wayback Machine Encyclopædia Britannica
  107. "Communicable Diseases Department, Leprosy FAQ". World Health Organization. 2006-05-25. Archived from the original on 2010-02-01. Retrieved 2010-01-31.
  108. Japan repealed its "Leprosy Prevention Laws" in 1996, but former patients still reside in sanatoriums. "Koizumi apologises for leper colonies". BBC News. May 25, 2001. Archived from the original on April 17, 2009. and Former Hansen's disease patients still struggling with prejudice Japan Times June 7, 2007 Archived August 26, 2009, at the Wayback Machine.
  109. Arch Dermato Syphilis 1898; 44:159–174
  110. Gussow, Zachary (1989). Leprosy, Racism, and Public Health. Boulder, Colorado: Westview Press. ISBN 978-0-8133-0674-2.
  111. "Leprosy". www.who.int. Retrieved 2019-07-23.
  112. "WHO | WHO donated MDT". WHO. Retrieved 2019-07-23.
  113. Singh, Kunwar Sahab; Pandey, Bam Deo (March 2012). "Leprosy—Hidden Disease?". Science Reporter. 49 (3).
  114. Jacob, Jesse; Franco-Paredes, Carlos (2008). "The stigmatization of leprosy in India and its impact on future approaches to elimination and control". PLoS Neglected Tropical Diseases. 2 (1): e113. doi:10.1371/journal.pntd.0000113. PMC 2217676. PMID 18235845.
  115. Grzybowski, Andrzej; Nita, Małgorzata (2016-01-01). "Leprosy in the Bible". Clinics in Dermatology. 34 (1): 3–7. doi:10.1016/j.clindermatol.2015.10.003. ISSN 0738-081X. PMID 26773616.
  116. [See: Orr, James, M.A., D.D. General Editor. "Entry for 'LEPER; LEPROSY'". "International Standard Bible Encyclopedia". 1915. Access-date=January 6, 2017
  117. Covey, Herbert C. (2001). "People with leprosy (Hansen's disease) during the Middle Ages" (PDF). Social Science Journal. 38 (2): 315–321. doi:10.1016/S0362-3319(01)00116-1. Archived from the original (PDF) on August 15, 2016. Retrieved June 25, 2016.
  118. Le Goff, Jacques (1990). The Medieval world. London: Collins & Brown. ISBN 978-1-85585-081-1.
  119. Clay, Rotha (1909). The Mediaeval Hospitals of England. Cornell University Library. ISBN 978-1-112-20443-2.
  120. Rubin, Stanley (1974). Medieval English medicine. New York: Barnes & Noble Books: Newton Abbot: David & Charles. ISBN 978-0-06-496016-8.
  121. Covey, Herbert C (2001-06-01). "People with leprosy (Hansen's disease) during the Middle Ages". The Social Science Journal. 38 (2): 315–321. doi:10.1016/S0362-3319(01)00116-1. ISSN 0362-3319.
  122. Moore, R. I. (2007). The Formation of a Persecuting Society. Oxford: Blackwell. ISBN 978-1-4051-2964-0.
  123. Alter, Andrea (2010). Genetic susceptibility to leprosy. McGill University (Canada): ProQuest Dissertations Publishing. ISBN 978-0-494-72613-6.
  124. Svein Atle Skålevåg. "Daniel Cornelius Danielssen". Store norske leksikon. Archived from the original on January 13, 2017. Retrieved January 1, 2017.
  125. Svein Atle Skålevåg (2014-09-28). "Carl Wilhelm Boeck". Store norske leksikon. Archived from the original on January 13, 2017. Retrieved January 1, 2017.
  126. White, Cassandra (2005). "Explaining a Complex Disease Process: Talking to Patients about Hansen's Disease (Leprosy) in Brazil". Medical Anthropology Quarterly. 19 (3): 310–330. doi:10.1525/maq.2005.19.3.310. ISSN 0745-5194. JSTOR 3655365. PMID 16222964.
  127. Barret, Ronald (June 2005). "Self-Mortification and the Stigma of Leprosy in Northern India". Medical Anthropology Quarterly. 19 (2): 216–230. doi:10.1525/maq.2005.19.2.216. ISSN 1548-1387. JSTOR 3655487. PMID 15974328.
  128. "Leprosy elimination: World Health Organization". Archived from the original on 2014-03-14. Retrieved 2019-07-03.
  129. Staples, James (2014). "Communities of the afflicted: constituting leprosy through place in South India". Medical Anthropology: Cross-Cultural Studies in Health and Illness. 33 (1): 6–20. doi:10.1080/01459740.2012.714021. PMID 24383749.
  130. Tayman, John (2007). The Colony: The Harrowing True Story of the Exiles of Molokai. New York: Simon and Schuster. ISBN 978-0-7432-3301-9. Archived from the original on 2016-01-02.
  131. Hamilton, Bernard (2000). The leper king and his heirs: Baldwin IV and the Crusader Kingdom of Jerusalem. Cambridge, UK: Cambridge University Press. ISBN 978-0-521-64187-6.
  132. Webber, Roger (2015). Disease Selection: The Way Disease Changed the World. CABI. p. 8. ISBN 978-1-78064-682-4. Archived from the original on 2017-09-08.
  133. Cung giu Nguyên (1955). "Contemporary Vietnamese Writing". Books Abroad. University of Oklahoma. 29 (1): 19–25. doi:10.2307/40093803. JSTOR 40093803.
  134. Bryant A (1995). Sekigahara 1600: The Final Struggle for Power (Campaign Series, 40). Osprey Publishing (UK). ISBN 978-1-85532-395-7. Retrieved 2010-02-28.
  135. Truman, Richard (2005). "Leprosy in wild armadillos". Lepr Rev. 76 (3): 198–208. PMID 16248207.
  136. Sharma, Rahul; Lahiri, Ramanuj; Scollard, David M.; Pena, Maria; Williams, Diana L.; Adams, Linda B.; Figarola, John; Truman, Richard W. (2013-01-01). "The armadillo: a model for the neuropathy of leprosy and potentially other neurodegenerative diseases". Disease Models & Mechanisms. 6 (1): 19–24. doi:10.1242/dmm.010215. ISSN 1754-8403. PMC 3529335. PMID 23223615.
  137. Job, C. K.; Drain, V.; Truman, R.; Deming, A. T.; Sanchez, R. M.; Hastings, R. C. (2016-06-01). "The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies to PGL-1". Indian Journal of Leprosy. 64 (2): 137–151. ISSN 0254-9395. PMID 1607712.
External resources
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.